Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes
Clinical Pharmacology: Advances and Applications · 2025-08 · Volume 17 · 253-267
DOI: 10.2147/cpaa.s497906 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology: Advances and Applications, 2025-08. Verfasst von Artemis Kyriakidou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessalo…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
- Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.
- Laboratory of Forensic Medicine & Toxicology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
ORCID-Profile: Artemis Kyriakidou, Theocharis Koufakis, Helen Gika, Kalliopi Kotsa
Zitieren
APA
Kyriakidou, A., Koufakis, T., Gika, H., & Kotsa, K. (2025). Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes. Clinical Pharmacology: Advances and Applications, Volume 17, 253-267. https://doi.org/10.2147/cpaa.s497906
Vancouver
Kyriakidou A, Koufakis T, Gika H, Kotsa K. Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes. Clinical Pharmacology: Advances and Applications. 2025;Volume 17:253-267. doi:10.2147/cpaa.s497906
BibTeX
@article{Kyriakidou2025,
author = {Kyriakidou, Artemis and Koufakis, Theocharis and Gika, Helen and Kotsa, Kalliopi},
title = {Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes},
journal = {Clinical Pharmacology: Advances and Applications},
year = {2025},
volume = {Volume 17},
pages = {253--267},
doi = {10.2147/cpaa.s497906}
}
EUVIMED